Difference between COLD AIHA and Warm AIHA
Reading File
Finding Sources
Finding Sources
Searching PubMed
"autoimmune hemolytic anemia"[MeSH Terms] AND "cold agglutinin"
Reading File
Reading File
Reading File
Reading File
Reading File
I now have excellent, comprehensive material from Goldman-Cecil Medicine and Washington Manual to give a thorough comparison. Here is the full answer:
Autoimmune Hemolytic Anemia (AIHA): Warm vs. Cold
AIHA occurs when autoantibodies target the patient's own RBCs, causing either extravascular or intravascular hemolysis. The distinction between warm and cold subtypes is critical because the antibody type, mechanism of hemolysis, site of destruction, and treatment are all different.
Overview / Frequency
| Feature | Warm AIHA | Cold AIHA (Cold Agglutinin Disease, CAD) |
|---|---|---|
| Proportion of AIHA cases | 70-80% of all AIHA | 15-20% of all AIHA |
| Age at onset | Any age; median ~58 years | Older adults; median ~67 years |
| Sex predominance | Female > male (1.5:1) | Female predominance |
| Paroxysmal Cold Hemoglobinuria (PCH) | - | Rare subtype; mainly children |
Antibody Type and Thermal Reactivity
| Feature | Warm AIHA | Cold AIHA |
|---|---|---|
| Antibody class | IgG (mainly IgG1 isotype) | IgM |
| Optimal temperature | 37°C (body temperature) | Below 30°C; optimum at 4°C |
| Complement activation | Variable (IgG can fix complement in some) | Always fixes complement (IgM is highly efficient at classical pathway activation) |
| Antigen targets | Rhesus system (~1/3), Band 3 protein, glycophorin A, Kell, Duffy | Polysaccharides - predominantly I/i antigens; Pr glycoprotein |
| Anti-I vs Anti-i specificity | N/A | Anti-I: Mycoplasma pneumoniae; Anti-i: Infectious mononucleosis (EBV) |
Etiology / Causes
Warm AIHA:
- Primary (idiopathic): ~40-50% of cases
- Secondary (50-60%): lymphoma, CLL, collagen vascular disease (SLE), drugs (methyldopa, penicillin, cephalosporins)
Cold AIHA:
- In children/young adults: usually acute and secondary to infection (Mycoplasma pneumoniae, EBV/CMV, infectious mononucleosis)
- In adults >50 years (chronic form): associated with IgM paraprotein or lymphoproliferative disorder in ~50% of cases; remainder are primary/idiopathic
- Note: SARS-CoV-2 infection has also been associated with cold AIHA
Mechanism and Site of Hemolysis
| Feature | Warm AIHA | Cold AIHA |
|---|---|---|
| Primary mechanism | IgG binds RBC at 37°C → macrophage Fc-gamma receptor engagement → phagocytosis | IgM binds RBC in cold peripheral circulation → complement activation → C3b opsonization |
| Type of hemolysis | Mainly extravascular | Mainly extravascular (liver-predominant) + some intravascular |
| Primary site | Spleen (reticuloendothelial system) | Liver (Kupffer cells process C3b-coated RBCs) |
| Complement involvement | Partial/variable | Prominent - IgM fixes C3 → C3b coats RBC → liver destruction |
The IgM cold agglutinin binds RBCs in cooler peripheral areas (fingers, toes, ears), activates complement to C3b, then the IgM detaches when blood returns to core temperature - but C3b stays fixed. This is why the DAT is C3-positive but IgG-negative in cold AIHA.
Clinical Features
| Feature | Warm AIHA | Cold AIHA |
|---|---|---|
| Onset | Can be acute or chronic | Often chronic; acute in post-infectious cases |
| Symptoms of hemolysis | Fatigue, pallor, jaundice, dark urine | Fatigue, pallor, jaundice |
| Cold-triggered symptoms | Absent | Acrocyanosis (bluish discoloration of fingers, toes, nose, ears in cold), Raynaud's phenomenon |
| Hemoglobinuria | Present if intravascular component | Present especially in PCH and severe CAD |
| Peripheral smear | Spherocytes, occasional fragmented RBCs | RBC agglutination (clumping visible on smear and in tube) |
Laboratory Findings
| Test | Warm AIHA | Cold AIHA |
|---|---|---|
| Direct Antiglobulin Test (DAT / Direct Coombs) | IgG positive; C3 positive or negative | IgG negative; C3 positive |
| Cold agglutinin titer | Normal | Elevated (>1:64 significant) |
| Peripheral smear | Spherocytes | RBC agglutination, rouleaux |
| LDH | Elevated | Elevated |
| Haptoglobin | Decreased | Decreased |
| Bilirubin (indirect) | Elevated | Elevated |
| Reticulocyte count | Elevated | Elevated |
Key DAT pattern to memorize:
- Warm AIHA = IgG+ (with or without C3)
- Cold AIHA = C3+ only (IgG negative, because IgM elutes off the RBC before testing)
Treatment
| Treatment | Warm AIHA | Cold AIHA (CAD) |
|---|---|---|
| First line | Glucocorticoids (prednisone 1-2 mg/kg/d) - effective in 80-90% | Avoid cold exposure (most important); rituximab (first-line pharmacotherapy) |
| Glucocorticoids | Yes - mainstay | Not effective - do NOT use |
| Splenectomy | Second-line option (effective, but declining use due to infection/thrombosis risk) | Not effective - avoid |
| Rituximab (anti-CD20) | Second-line (375 mg/m² x4 weeks, ~80% response rate); also low-dose 100 mg x4 effective | First-line drug therapy; can use alone or with bendamustine |
| Transfusion | Use if severe anemia; crossmatch challenging | Transfuse through blood warmer at 37°C; keep room warm |
| Plasma exchange | Occasionally used | Effective (removes 60-70% of IgM) - temporary control in severe hemolysis |
| Refractory disease | Azathioprine, cyclophosphamide, cyclosporine, mycophenolate mofetil | Bendamustine + rituximab combination |
| Complement inhibitors | Emerging therapies | Sutimlimab (anti-C1s) approved for CAD |
Special Subtype: Paroxysmal Cold Hemoglobinuria (PCH)
- Caused by Donath-Landsteiner antibody (IgG hemolysin, not IgM)
- Reacts with RBCs at low temperatures (2-10°C), causes lysis upon rewarming
- Detected by the Donath-Landsteiner test (only available in referral labs)
- Seen almost exclusively in children, often post-viral
- DAT: C3-positive, IgG variable
Summary Mnemonic
"WARM = IgG, Spleen, Steroid-responsive"
"COLD = IgM, Liver/Complement, Steroid-resistant, avoid the cold"
Sources: Goldman-Cecil Medicine, Chapter 146; Washington Manual of Medical Therapeutics, Hematology Chapter; Tintinalli's Emergency Medicine, Chapter 237
Difference between COLD AIHA and Warm AIHA
I already covered this in full detail just above! Here's a quick recap of the key differences:
Warm vs. Cold AIHA - Quick Comparison
| Feature | Warm AIHA | Cold AIHA |
|---|---|---|
| Frequency | 70-80% of AIHA | 15-20% of AIHA |
| Antibody | IgG | IgM |
| Optimal temp | 37°C | <30°C (optimum 4°C) |
| Complement | Variable | Always fixed |
| Antigen target | Rh system, Band 3, Glycophorin A | I/i antigens |
| Hemolysis site | Spleen (extravascular) | Liver (extravascular) + some intravascular |
| DAT pattern | IgG+ (± C3) | C3+ only (IgG negative) |
| Peripheral smear | Spherocytes | RBC agglutination |
| Cold agglutinin titer | Normal | Elevated (>1:64) |
| Causes | SLE, CLL, lymphoma, drugs, idiopathic | Mycoplasma/EBV (acute); lymphoma/IgM paraprotein (chronic) |
| Clinical clue | Jaundice, fatigue | + Acrocyanosis, Raynaud's in cold |
| First-line Rx | Glucocorticoids (80-90% response) | Avoid cold + Rituximab |
| Steroids effective? | Yes | No |
| Splenectomy effective? | Yes (second-line) | No |
| Transfusion | Standard crossmatch | Must use blood warmer (37°C) |
Memory hook: "WARM = IgG, Spleen, Steroid-sensitive" / "COLD = IgM, Liver, Complement, Steroid-resistant"
The full detailed breakdown with mechanisms, causes, and treatment protocols is in my response directly above. Let me know if you want any specific aspect expanded!
This is a shared conversation. Sign in to Orris to start your own chat.